SCHEMBL5072272

SCHEMBL5072272

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccc(OC)cc1O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
C5AR1 P21730 1/20 0.39
BCHE P06276 3/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HDAC1 Q13547 1/20 0.37
DRD2 P14416 3/20 0.37
DRD3 P35462 3/20 0.37
CNR2 P34972 2/20 0.37
ATP4A P20648 1/20 0.36
ATP4B P51164 1/20 0.36
PDE4B Q07343 1/20 0.36
GNRHR P30968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137886 0.90 GNRHR (0.41) GAAC5AR1BCHEKDM4EALDH1A1
SCHEMBL5137859 0.90 ALDH1A1 (0.41) GAAC5AR1BCHEKDM4EALDH1A1
SCHEMBL5135916 0.89 TP53 (0.43) GAAC5AR1BCHEKDM4EALDH1A1
SCHEMBL5136569 0.88 C5AR1 (0.43) GAAMAPTC5AR1BCHEKDM4E
SCHEMBL5134702 0.88 ALDH1A1 (0.42) GAAMAPTC5AR1BCHEKDM4E
SCHEMBL5135241 0.86 C5AR1 (0.42) GAAC5AR1BCHEKDM4EALDH1A1
SCHEMBL5136819 0.86 TSPO (0.40) GAAMAPTC5AR1BCHEKDM4E
SCHEMBL5137427 0.86 GNRHR (0.41) GAAC5AR1KDM4EALDH1A1TSHR
SCHEMBL5075063 0.85 TP53 (0.42) GAAMAPTC5AR1BCHEKDM4E
SCHEMBL5134931 0.85 CALM1 (0.44) C5AR1BCHEKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed